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comprises mainly advances in treatment planning - in particular in 
regard of individual target (re-)definition based on tumour response 
and in regard of individual dwell time optimisation for improvement of 
the dose distribution: Repetitive imaging is necessary and allows for 
identification of tumour regression and organ changes. MRI is currently 
considered as the gold standard for the assessment of local tumour 
extension in cervical cancer and is therefore the method of choice for 
IGABT, however, CT, PET-CT and ultrasound were also described as 
feasible for brachytherapy treatment planning. With MRI, the target 
concept (high risk clinical target volume - HR CTV, intermediate risk 
clinical target volume - IRCTV) for IGABT after external beam 
radiotherapy and chemotherapy implies the residual macroscopic 
tumour (GTV at brachytherapy), the surrounding tumour regression 
area (“grey zones”), the complete remaining cervix and the tumour 
extension at diagnosis with different dose aims respectively. The 
optimal fractionation scheme still remains unclear, but it was shown 
that a local control rate > 95% is achievable, if a D90 ≥ 87 Gy (EQD2) is 
delivered to the HR CTV. To reach this dose aim, the implantation of 
interstitial needles in addition to the standard applicator system may 
be necessary – especially in locally advanced tumours with extensive 
residual parametrial involvement or with unfavourable topography. 
The use of supplementary interstitial needles allows to increase and 
further shape the treated volume in order to avoid low dose regions 
within the target volumes and/or high dose delivery to surrounding 
organs at risk. The reduction of unintended dose to the surrounding 
organs at risk by IGABT confers a significant decrease in morbidity as 
shown in retrospective studies and recently in the prospective STIC 
trial.The D2cc appears to be a reliable predictor for typical severe 
rectal brachytherapy related side-effects such as bleeding caused 
by teleangiectasia, ulceration and fistula as well as a potential (but 
less stable) indicator for localized bladder toxicity. It could be 
demonstrated that a D2cc of 73 Gy (EQD2) for grade 1-4 side effects 
and 78 Gy (EQD2) for grade 2-4 side effects leads to a 10% probability 
for the respective rectal side effects. Dosimetric comparisons 
between standard treatment plans based on dose points and IGABT 
showed a clear superiority of IGABT. Retrospective mono-institutional 
clinical results in 156 patients showed a local control rate of 95% and 
6% grade 3 and 4 gastrointestinal and urogenital side effects after 3 
years. The preliminary results from the retrospective multi-centre 
study “RetroEMBRACE” with 11 participating centres seem to confirm 
these results with 89% local control rate after 5 years in 645 patients. 
The prospective multi-centre trial “STIC” demonstrated a reduction of 
treatment related side effects by IGABT by 50% compared to standard 
x-ray based brachytherapy. Further evidence on IGABT is expected 
from the prospective multicenter study “EMBRACE”, which currently 
recruited about 800 patients. 
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There is considerable interest in approaches that could improve the 
therapeutic window of radiotherapy. As our understanding of cancer 
biology has expanded, novel candidate strategies have emerged in 
order to conteract the mechanisms of tumor radioresistance which 
may explain the therapeutic failures after radiotherapy. 
Drugs which target the G2/M checkpoint after irradiation, lead  to an 
increase in mitotic death are candidates which may induce an 
increase in tumor cell kill while relatively sparing non tumor tissues 
Drugs such as CHK1 inhibitors, preferentially induce an override of the 
cycle check-points after IR, based on the p53 status. 
HDAC inhibitors are drugs which have in common the ability to 
hyperacetylate both histone and non histone targets, resulting in 
avariety of effects on cancer cells, their microenvironment, and 
immune responses. Data suggest that HDAC inhibitors not only induce 
widespread histoneacetylation but also increase in reactive oxygen 
species and DNA damage.  ROS account for the DNA damage observed 
with HDACi treatment, DNA damage can also be the result of changes 
in the DNA repair activity and chromatin remodeling factors. This 
approach is currently being tested at our institution. 
mTOR is one the the downstream effectors of thePI3K-AKT pathway 
which plays a role in angiogenesis and hypoxic metabolism.mTOR 
inhibitors are currently approved as stand alone treatments and the 
combination of mTOR inhibitors with ionizing radiation has been 
evaluated in the setting of early clinical trials. 
The major challenges of these novel approaches is the assessment of 
their clinical usefulness. This implies not only to show increased 
tumor cell kill in preclinical assays, but also to define which tumor 
biological background is optimal (the biomarker aspect), which are 
the appropriate schedules and intervals between drug administration 
and irradiation. Notwithstanding, a cornerstone is the impact of any 
novel approach on normal tissue response to irradiation and the 
consequences on the tumor versus normal tissue therapeutic ratio. 
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Poly(ADP-ribose)polymerase (PARP) is a DNA repair enzyme that 
facilitates repair of radiation induced DNA single strand breaks. It is 
well established that chemical inhibitors of PARP increase radiation 
sensitivity of tumour cells in vitro and enhance tumour growth delay 
in pre-clinical animal models of cancer. PARP inhibitors also have 
single agent activity against BRCA-deficient breast and ovarian 
cancers and a number of compounds have been tested in early phase 
clinical trials in this setting. Toxicity profiles areacceptable and many 
patients tolerate long-term treatment without significant adverse 
effects. 
Mechanistic studies in vitro have shown that the radiopotentiating 
effects of PARP inhibitors are observed only in replicating cells, and 
there is also evidence to support enhanced sensitisation in DNA repair 
defective cells. Both observations indicate the potential for tumour 
specific enhancement of the cytotoxic effects of radiation and support 
the argument to combine PARP inhibitors with radiation therapy in the 
clinic. 
Despite the clear rationale, progress has been slow and at the time of 
writing only three clinical trials combining PARP inhibitors with 
radiation have opened to recruitment. To some extent, this can be 
explained a lack of validated clinical trials designs for radiation/drug 
combinations. Equally important is the observation that PARP 
inhibitors exacerbate haematological toxicity when delivered in 
combination with chemotherapy drugs such as temozolomide or 
cisplatin. Since curative radiation therapy regimes often include 
concomitant chemotherapy agents, alternative approaches are 
required. 
In this presentation I will summarise the relevant pre-clinical data, 
give an update on clinical experiences and consider new approaches 
by which PARP inhibitors and radiation therapy might be safely and 
effectively combined. 
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Solid tumours such as glioblastoma contain a cell subset endowed with 
stem properties (cancer stem cells), which is required and sufficient 
to drive tumour onset and propagation, as well as it is responsible for 
resistance to conventional therapies, and tumour relapse. It has been 
shown that glioblastoma stem cells are radioresistant, likely because 
they activate the DNA repair machinery more efficiently than the 
remaining non-stem cancer cells, which, conversely, may be 
destroyed by radiotherapy. We have recently shown that cancer stem 
cell radioresistance is associated with overexpression and activation 
of the MET oncogene, encoding the tyrosine kinase receptor for HGF, 
known to regulate cancer ‘invasive growth’. MET overexpression is 
reported in significant percentages of tumours of various origins, 
including 30% of glioblastomas, often in association with poor 
prognosis. We have shown that ionizing radiation, through activation 
of DNA repair mechanisms and transcription factor NF-kB, sustains 
MET overexpression and activity. In glioblastoma, MET signalling 
results in hyperactivation of the PI3-kinase/AKT pathway, protection 
against radiation-induced apoptosis, and positive selection of the 
cancer stem cell subpopulation. Conversely, we have shown that 
targeted MET inhibition, by small-molecule kinase inhibitors or 
monoclonal antibodies, may radiosensitize cells in vitro and in vivo. 
Therefore, in glioblastoma and, possibly, other tumours, combination 
of MET inhibitors with radiotherapy offers a promising strategy to 
destroy cancer stem cells, and prevent tumour relapse.  
   
 
